Compass Pathways Launches Proposed $150.0 Million Public Offering
Stocks in this Quantisnow insightHealth Care
Historical context for CMPS
Across the 9 sessions after earlier CMPS headlines, the stock closed higher 6 times and lower 3 times, with a median move of 5.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CMPS | SPY |
|---|---|---|---|
| Feb 17, 2026 | Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depressionand 1 other headline that session | +31.3% | +0.2% |
| Jan 6, 2026 | Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 | +7.5% | +0.6% |
| Dec 10, 2025 | COMPASS Pathways upgraded by Oppenheimer with a new price target | +5.2% | +0.7% |
| Dec 9, 2025 | Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET | +1.0% | -0.1% |
| Nov 20, 2025 | Compass Pathways to Participate in Two Investor Conferences in December | -1.0% | -1.5% |
| Nov 5, 2025 | Compass Pathways to Participate in Stifel 2025 Healthcare Conference | -17.2% | +0.3% |
Quantisnow market dataNASDAQ
CMPS
COMPASS Pathways Plc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for CMPS
Full CMPS profile on Quantisnow Follow CMPS and get a push notification the moment its next story breaks.